Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)
Phase 3
Completed
- Conditions
- Androgenetic Alopecia
- Registration Number
- NCT00396175
- Lead Sponsor
- Organon and Co
- Brief Summary
A clinical study to collect additional data in order to characterize the reduction in PSA with finasteride 1 mg, and its reversibility in men with androgenetic alopecia between the ages of 40 to 60 years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 355
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Serum Prostatic Specific Antigen (PSA) after 48 weeks of treatment
- Secondary Outcome Measures
Name Time Method Reversibility of effects on Serum Prostatic Specific Antigen (PSA) after 24 weeks off drug